SITC Archive Library

SITC 30th Anniversary Annual Meeting and Pre-Conference Programs (2015): Adoptive Immunotherapy
November 6-8, 2015
Gaylord National Hotel & Convention Center National Harbor, MD

Session Co-Chairs
Malcolm K. Brenner, MD, PhD – Baylor College of Medicine
Bruce Levine, PhD – Abramson Cancer Center, University of Pennsylvania

SITC 30th Anniversary Annual Meeting Organizers
Sandra Demaria, MD – Weill Cornell Medical College
Madhav Dhodapkar, MD – Yale University
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre
Jennifer A. Wargo, MD – University of Texas MD Anderson Cancer Center
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute

Program Summary
This session at the SITC 30th Anniversary Annual Meeting on Friday, November 6, 2015 in National Harbor, MD featured recent studies using multiple approaches to improve the efficacy of immunotherapies and the path forward from B cell malignancies to developing successful therapies for solid cancers. Recent publications have demonstrated remarkable successes of adoptive T cell therapy for cancer, such as the use of T lymphocytes genetically engineered to express chimeric antigen receptors (CAR) or T Cell Receptors. Adoptive immunotherapy targeting viruses may be leveraged to include CARs targeting B cell malignancies. Regulatory T cells have applications in the reduction of morbidity and mortality following stem cell transplantation. 

About the SITC 30th Anniversary Annual Meeting
SITC's 30th Anniversary Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving the outcome for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy research. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for both structured and informal discussions including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as ongoing SITC projects.

Target Audience
The target audience for this program included basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, researchers, graduate students, post-doctoral fellows, and allied health professionals involved in cancer research as well as pharmacists and payers that wished to learn more about cancer immunology and immunotherapy and its incorporation into current (and future) effective cancer treatment.

#2015 #AnnualMeeting #BrainCancers 
#Melanoma #PresentationSlides #SITC #AdoptiveCellTherapy #Clinician 
#Industry #Oncologist #Researcher #Video